Asian Market Gems: Penny Stocks To Watch In May 2025

In This Article:

As the Asian markets navigate a complex landscape of trade discussions and economic shifts, investors are keenly watching for opportunities that might arise amid these developments. Penny stocks, often overlooked due to their small size or early-stage nature, can still offer intriguing growth potential when backed by robust financial health. In this article, we explore three penny stocks that stand out for their balance sheet strength and potential to uncover hidden value in today's market conditions.

Top 10 Penny Stocks In Asia

Name

Share Price

Market Cap

Financial Health Rating

T.A.C. Consumer (SET:TACC)

THB4.58

THB2.75B

★★★★★★

CNMC Goldmine Holdings (Catalist:5TP)

SGD0.40

SGD162.12M

★★★★★☆

Beng Kuang Marine (SGX:BEZ)

SGD0.186

SGD37.05M

★★★★★★

Yangzijiang Shipbuilding (Holdings) (SGX:BS6)

SGD2.20

SGD8.66B

★★★★★☆

BRC Asia (SGX:BEC)

SGD3.13

SGD858.72M

★★★★★★

Ever Sunshine Services Group (SEHK:1995)

HK$1.94

HK$3.35B

★★★★★☆

Bosideng International Holdings (SEHK:3998)

HK$4.38

HK$50.14B

★★★★★★

Lever Style (SEHK:1346)

HK$1.18

HK$744.52M

★★★★★★

Goodbaby International Holdings (SEHK:1086)

HK$1.35

HK$2.25B

★★★★★★

TK Group (Holdings) (SEHK:2283)

HK$2.16

HK$1.8B

★★★★★★

Click here to see the full list of 1,178 stocks from our Asian Penny Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Jacobio Pharmaceuticals Group

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Jacobio Pharmaceuticals Group Co., Ltd. is an investment holding company focused on the in-house discovery and development of oncology therapies, with a market cap of approximately HK$3.30 billion.

Operations: The company generated CN¥155.71 million from its segment dedicated to the research and development of new drugs.

Market Cap: HK$3.3B

Jacobio Pharmaceuticals Group, with a market cap of approximately HK$3.30 billion, is navigating the challenging landscape of oncology drug development as a pre-revenue entity. The company reported CN¥155.71 million in revenue from R&D activities but remains unprofitable despite reducing losses over five years by 29.6% annually. Its robust cash position covers both short and long-term liabilities, providing a cash runway exceeding three years even if free cash flow continues to decline at historical rates. Recent developments include advanced clinical trials for its SHP2 inhibitor, sitneprotafib, highlighting potential breakthroughs in cancer treatment pipelines across global markets.